The burgeoning landscape of therapy for weight management and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant differences in their pharmacological profiles and clinical study results are emerging. Retatru

Showing promise in the field of excess body fat therapy, retatrutide presents a distinct approach. Different from many current medications, retatrutide works as a dual agonist, at once targeting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. The concurrent stimulation encourages multiple beneficial effe